Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as an injectable powder for solution for injection for intramuscular or subcutaneous administration. It provides exogenous FSH and LH activity to stimulate ovarian follicular development and estrogen production, supporting ovulation induction and controlled ovarian hyperstimulation in women with infertility.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across EU and global markets.

Menopur is a gonadotropin used in reproductive medicine to support follicular growth and ovulation. - Anovulation: induces ovulation in women with anovulatory infertility. - Controlled ovarian hyperstimulation: enhances follicular development for assisted reproductive technologies such as IVF. - Induction of ovulation in infertility treatment: facilitates ovulation in patients undergoing fertility therapy.

Menopur may be associated with a range of adverse reactions, which are generally related to its hormonal activity and injection site.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Abdominal bloating: transient abdominal distension. - Headache: mild headache episodes. - Nausea: occasional nausea. - Mood changes: mild emotional lability. - Ovarian hyperstimulation symptoms: mild ovarian enlargement.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe fluid shift and thrombosis risk. - Multiple pregnancy: increased chance of twins or higher‑order gestations. - Thromboembolic events: rare blood clot formation. - Allergic reaction: anaphylaxis or severe hypersensitivity.

Prior to initiating Menopur therapy, clinicians should consider several precautionary measures to ensure patient safety. - Baseline assessment: perform ultrasound and hormone evaluation before treatment. - Ovarian monitoring: conduct regular ultrasound to detect excessive follicular response. - OHSS risk: assess patient history for risk factors such as polycystic ovary syndrome. - Pregnancy testing: confirm negative pregnancy test before starting therapy. - Concomitant hormones: avoid use with other gonadotropins unless medically indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications that affect hormonal balance or coagulation.

Major Interactions (Avoid): - GnRH agonists/antagonists: may alter gonadotropin response if not coordinated. - Anticoagulants: increased risk of bleeding with severe OHSS. - Estrogen‑containing products: may interfere with intended hormonal stimulation.

Moderate Interactions (Monitor Closely): - Thyroid hormones: monitor thyroid function as gonadotropins can affect metabolism. - Corticosteroids: may mask OHSS symptoms. - Diuretics: can influence fluid balance during OHSS.